Insmed reported $107.4M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
BioMarin Pharmaceutical USD 825M 80M Jun/2025
Cytokinetics USD 66.76M 65.16M Jun/2025
DBV Technologies USD 1.46M 712K Jun/2025
Dynavax Technologies USD 95.44M 30.44M Jun/2025
Gilead Sciences USD 7.1B 430M Jun/2025
Insmed USD 107.4M 14.58M Jun/2025
Novartis USD 14.84B 1.28B Jun/2025
Regeneron Pharmaceuticals USD 3.68B 650M Jun/2025
Sarepta Therapeutics USD 611.09M 163.81M Jun/2025
Ultragenyx Pharmaceutical USD 166.5M 27.21M Jun/2025
Vertex Pharmaceuticals USD 2.96B 190M Jun/2025